Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP232
- Development stage
- Preclinical
- Lead developer
- University of Tennessee Health Science Center
01
Overview
AP232: sourced facts only. name: "Here, we report on the development of AP232 that targets the U2 auxiliary homology motif (UHM) of U2AF1, based on our previously reported SF153." [PMID:41089473]; target: "Here, we report on the development of AP232 that targets the U2 auxiliary homology motif (UHM) of U2AF1, based on our previously reported SF153." [PMID:41089473]; developer: "Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States." [PMID:41089473]; stage: "AP232 exerted anti-leukemia activity, with higher activities observed in cell lines carrying splicing factor mutations." [PMID:41089473]
02
Targets
U2AF1
Beyond the preview
Go deeper on AP232.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP232.